Clinical trials: Metastatic Malignant Neoplasm to Brain
Brain Metastases
Whole-Brain Radiotherapy (WBRT) Versus WBRT and Integrated Boost Using Helical Tomotherapy for Multiple Brain Metastases
Brain metastases occur in 20-40% of patients with primary extracerebral tumors. Despite important advances in therapy of malignant solid tumors and treatment of 1-3 brain metastases, multiple brain metastases continue to present…
- Trial name
- NCT00876759
- Testing
- whole brain radiotherapy, whole brain radiotherapy with simultaneous boost
- Where
- 5 sites in Germany
- Volunteers
- 160 people
- Sponsor
- University Hospital, Essen
Neoplasms, Breast
Brain Metastases In ErbB2-Positive Breast Cancer
This study is for patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic…
- Trial name
- NCT00437073
- Testing
- capecitabine, topotecan, lapatinib
- Where
- 44 sites in United States, Austria and 9 more
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer Metastatic
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Objective:Patients with asymptomatic or minimally symptomatic Stage IV EGFR-positive NSCLC with baseline intracranial metastases.
- Trial name
- NCT05800223
- Testing
- Almonertinib, SBRT
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Cancer Hospital, China
Intracranial Glioma, Metastatic Brain Tumor
F-Tryptophan PET/CT in Human Cancers
Imaging procedures such as 1-(2-[18F]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future.
- Conditions
- Intracranial Glioma, Metastatic Brain Tumor, Breast Cancer, Neuroendocrine Tumors
- Trial name
- NCT05556473
- Testing
- 1-(2-[18F]FLUOROETHYL)-L-Tryptophan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Brain Metastases
Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases
The aim of this study is to evaluate the clinical efficacy and safety of continuous Endostar infusion combined with radiotherapy for treatment of brain metastases.
- Trial name
- NCT01410370
- Testing
- 6MV-X ray, Endostar
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain.
- Conditions
- CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation
- Trial name
- NCT03994796
- Testing
- Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib
- Where
- 435 sites in United States
- Volunteers
- 50 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma Stage Iv
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
This is a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain…
- Trial name
- ABC-X (NCT03340129)
- Testing
- Ipilimumab, Nivolumab, Stereotactic Radiotherapy
- Where
- 9 sites in Australia, Norway
- Volunteers
- 218 people
- Sponsor
- Melanoma Institute Australia
Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
This pilot phase II trial study evaluates the usefulness of the ferumoxytol steady state magnetic resonance imaging (MRI) technique for response assessment after pembrolizumab and radiation therapy in non-small cell lung cancer…
- Trial name
- NCT03325166
- Testing
- Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Brain Metastases
MeDex: No Perioperative Dexamethasone in Brain Metastases
Perioperative treatment of newly diagnosed cancer patients with brain metastasis without dexamethasone (Dex).
- Trial name
- NCT07044557
- Testing
- Withholding perioperative Dexamethasone
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Louisville
Brain Metastases
SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
This study is conducted to compare the contrast effect and safety of SH L562BB with ProHance, which has already been approved as a pharmaceutical product of similar indication.
- Trial name
- NCT00522951
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875), ProHance
- Where
- 20 sites in Japan
- Volunteers
- 165 people
- Sponsor
- Bayer
Brain Metastases
MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
This study aims to assess changes in vascular permeability in the brain tumor, and in the surrounding brain, due to radiation therapy, using Magnetic Resonance Imaging (MRI).
- Trial name
- NCT02031237
- Testing
- Single Fraction Stereotactic Radiosurgery (SRS), Fractionated Whole Brain Radiation Therapy (WBRT), Fractionated Stereotactic Radiation Therapy (FSRT)
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Michigan Rogel Cancer Center
Brain Metastases
Prophylactic Cranial Irradiation (PCI) Versus no PCI in Non Small Cell Lung Cancer After a Response to Chemotherapy
1. Patients with confirmed advanced NSCLC and any response to 3-6 cycles of chemotherapy, were randomized to receive PCI (30 Gy/10fr) or no PCI. 2.
- Trial name
- PCI (NCT00745797)
- Testing
- Radiotherapy
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Yi-Long Wu
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer
The purpose of this study is to investigate the safety and imaging ability of 111In-DAC when used with planar and SPECT imaging for the detection of lung cancer and brain cancer consistent with metastatic lung cancer.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Metastases, Neoplasm
- Trial name
- NCT00040560
- Testing
- 111In-DAC, Diagnostic
- Where
- 2 sites in United States
- Sponsor
- Copharos
Brain Metastases
Phase 2 Trial in Multiple Brain Metastases Outcomes With HA-SIB-WBRT
Recently, the evidence supports hippocampal avoidance with whole brain radiotherapy (HA-WBRT) as the recommended treatment option in patients with good prognosis and multiple brain metastases as it gives better neurocognitive…
- Trial name
- NCT04452084
- Testing
- HA-WBRT, HA-SIB-WBRT
- Where
- Singapore
- Volunteers
- 42 people
- Sponsor
- National Cancer Centre, Singapore
Brain Metastases
Pre- Versus Post-operative SRS for Resectable Brain Metastases
The purpose of this study is to determine if performing radiotherapy (SRS) prior to surgery results in better treatment outcomes than performing surgery before radiotherapy for patients with brain metastases.
- Trial name
- NCT04474925
- Testing
- Brain Surgery, Stereotactic Radiosurgery
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- AHS Cancer Control Alberta
ALL, Childhood, Leukemia, Lymphoblastic
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
While neurocognitive impairments in attention, memory and executive functioning are commonly reported sequelae of childhood leukemia and brain tumors, studies have only recently begun to examine the treatment of attention…
- Conditions
- ALL, Childhood, Leukemia, Lymphoblastic, Leukemia, Lymphoblastic, Acute, Leukemia, Lymphoblastic, Acute, L1
- Trial name
- NCT01100658
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Minnesota
Lung Cancer, Non Small Cell Lung Cancer
A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
This is a Phase II, single-arm, multicenter trial for patients with metastatic non-small cell lung cancer who have brain metastases and no known actionable mutations.
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Brain Metastases
- Trial name
- TROPICAL-1 (NCT06822543)
- Testing
- Pembrolizumab, Datopotamab deruxtecan, Carboplatin
- Where
- 13 sites in Brazil
- Volunteers
- 46 people
- Sponsor
- Latin American Cooperative Oncology Group
Brain Metastases, Generalized Malignancy, Primary
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
The main purpose of this study is to see whether addition of TPI 287 to FSRT is safe and tolerable. Researchers also want to find out if adding TPI 287 to FSRT can help with better controlling the growth of brain lesions in…
- Conditions
- Brain Metastases, Generalized Malignancy, Primary, Brain Lesions
- Trial name
- NCT02187822
- Testing
- TPI 287, Fractionated Stereotactic Radiotherapy (FSRT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Breast Cancer to the Brain
18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain
The purpose of this study is to compare two different imaging methods to examine the response of brain metastases to WBRT. These two imaging methods will take pictures of the brain using : 1) a positron emission tomography (PET)…
- Trial name
- NCT01621906
- Testing
- 18F-FLT-PET Imaging
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leptomeningeal Disease, Glioblastoma
ctDNA-Guided Intraventricular Therapy for CNS Malignancies
This prospective, single-center study will evaluate whether cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) testing using the Belay Summit assay can improve the clinical management of patients with malignant gliomas or…
- Conditions
- Leptomeningeal Disease, Glioblastoma, Brain Metastases, Non-Small Cell Lung Cancer
- Trial name
- GUIDE-CNS (NCT07689721)
- Testing
- CSF ctDNA-Guided Clinical Management
- Volunteers
- 77 people
- Sponsor
- Alireza Mansouri
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.